Lipanor (Ciprofibrate)

Ciprofibrate activates the nuclear receptor peroxisome proliferator‑activated receptor alpha (PPARα). This activation increases the expression of enzymes such as lipoprotein lipase that clear triglyceride‑rich lipoproteins from the bloodstream and enhances fatty‑acid oxidation, while simultaneously decreasing hepatic triglyceride synthesis. The combined effect lowers plasma triglycerides and modestly raises HDL‑cholesterol.

The dosage of Lipanor is individualized by the prescribing healthcare professional based on the patient’s clinical condition, laboratory results, and tolerability. Physicians determine the appropriate strength and frequency, and patients should follow the prescribed regimen without making any changes unless directed by their clinician.

The safety of ciprofibrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare provider.

To request Lipanor, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and assistance with import documentation.

Compared with statins, ciprofibrate primarily targets triglyceride reduction rather than LDL‑cholesterol lowering. It is especially useful when triglycerides are markedly elevated or when statin therapy alone does not achieve target levels. Unlike niacin, ciprofibrate has a lower incidence of flushing but shares a similar risk of muscle‑related adverse effects when combined with certain statins.

Lipanor should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in their original container, protect them from moisture, heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances, and keep out of reach of children.

Lipanor is taken orally, usually once daily with a meal to enhance absorption and reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse reactions include rhabdomyolysis (severe muscle breakdown), significant hepatotoxicity (marked liver enzyme elevations or jaundice), and rare hypersensitivity reactions such as anaphylaxis. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as yellowing of the skin or eyes.

Lipanor is contraindicated in individuals with known hypersensitivity to ciprofibrate or any fibrate component, active liver disease, severe renal impairment, and in patients with a history of gallstones who are at high risk for biliary complications. It should also be avoided in patients currently taking contraindicated medications such as gemfibrozil or high‑dose simvastatin.